Sglt 2i CKD Farxiga denied due to quantity / dose limits by Cigna?
Quantity-limit denials usually flip when the appeal documents the clinically appropriate dose for the patient's weight, kidney function, or escalation schedule, citing the FDA label or specialty-society guideline.
US health-plan appeal rights
Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules
Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.
What Cigna typically requires
Cigna's specific coverage criteria for sglt2i ckd farxiga are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.
The Cigna angle on Sglt 2i CKD Farxiga
## Why Cigna Limits the Quantity of Farxiga for CKD — and How to Appeal
Quantity limits for dapagliflozin (Farxiga) under Cigna's benefit design are typically aligned with the dosing intervals and supply amounts specified in the FDA-approved prescribing information. A quantity-limit denial occurs when the prescription as written — whether in the number of tablets, the strength dispensed, or the days' supply requested — exceeds the parameters set in Cigna's coverage policy for this medication in the CKD indication.
This type of denial is among the most addressable on appeal, because it almost always comes down to a documentation gap rather than a fundamental clinical disagreement about whether the drug is appropriate.
### Why This Denial Is Commonly Overturned
Quantity-limit policies are designed around standard FDA-approved dosing. If your prescriber wrote for a quantity that is within FDA-approved parameters but exceeds Cigna's default supply limit (for example, a 90-day supply versus the default 30-day), a brief letter documenting the clinical rationale and confirming FDA-label alignment is frequently sufficient. If the quantity reflects a unique clinical circumstance — such as a different dosing schedule documented in your chart — the prescriber's explanation of the medical basis is the critical piece.
### Federal Appeal Framework
- Internal appeal (ACA / ERISA §503): File within the deadline on the denial letter. You are entitled to a full-and-fair review by a clinical reviewer not involved in the initial denial.
- External review (ACA §2719): If the internal appeal fails, file for independent external review within approximately four months of the final internal denial. The external decision is binding.
- Expedited option: Available when delay would seriously jeopardize health — decisions typically within 72 hours.
### Concrete Appeal Steps and Timeline
1. Pull the denial letter and identify the specific quantity limit that was exceeded and the policy basis Cigna cited. 2. Download Cigna's current coverage policy for Farxiga / SGLT2 inhibitors in CKD and locate the quantity-limit provision. 3. Pull the FDA-approved prescribing label for Farxiga and find the approved dosing and supply information. 4. Confirm that the prescribed quantity is within an FDA-approved dosing range — and document this comparison in writing. 5. Ask your prescriber to write a letter explaining why the prescribed quantity is medically necessary and how it aligns with the FDA label and the applicable clinical guidelines for CKD (citing the relevant guideline organization, such as KDIGO, without quoting specific numerical criteria). 6. File the internal appeal before the deadline. Track the external-review window.
### Documentation to Gather
- FDA prescribing label: Current Farxiga label with dosing section highlighted.
- Cigna coverage policy: The quantity-limit provision, printed with the effective date.
- CKD diagnosis records: Chart notes confirming diagnosis and treatment rationale.
- Prescriber letter: Documents the clinical basis for the prescribed quantity and its alignment with FDA-approved use.
### Criteria-Mapping Structure
For each quantity-limit criterion in Cigna's policy, provide a written response: either confirming alignment with the FDA label or explaining the clinical basis for deviation. The most effective appeals are structured so that a reviewer can verify every requirement without needing to search for the supporting documentation — attach and label each exhibit clearly.
Next steps
- Find the date on the denial letter — your appeal window starts there.
- Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
- Request the insurer's claim file in writing — they must provide it.
- Submit your appeal in writing with new clinical evidence and a physician statement.
Get the letter drafted
DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.
Start my appeal — $30 with code SEO25 →